HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 1 (January)

1. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.
   J Mol Biol, 375(4): 969-78. [Abstract] [Full-text]
2. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging.
   J Mol Biol, 375(4): 1098-112. [Abstract] [Full-text]
3. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.
   J Virol, 82(2): 903-16. [Abstract] [Full-text]
4. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
   J Virol, 82(2): 949-56. [Abstract] [Full-text]
5. Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins.
   J Virol, 82(2): 1021-33. [Abstract] [Full-text]
6. Mutations in the U5 region adjacent to the primer binding site affect tRNA cleavage by human immunodeficiency virus type 1 reverse transcriptase in vivo.
   J Virol, 82(2): 719-27. [Abstract] [Full-text]
7. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
   J Virol, 82(2): 987-98. [Abstract] [Full-text]
8. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
   J Virol, 82(2): 664-73. [Abstract] [Full-text]
9. Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.
   J Virol, 82(2): 805-16. [Abstract] [Full-text]
10. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).
    J Virol, 82(2): 764-74. [Abstract] [Full-text]
11. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.
    J Virol, 82(2): 638-51. [Abstract] [Full-text]
12. Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation.
    J Virol, 82(2): 893-902. [Abstract] [Full-text]
13. Molecular mimicry in inducing DNA damage between HIV-1 Vpr and the anticancer agent, cisplatin.
    Oncogene, 27(1): 32-43. [Abstract] [Full-text]
14. Different immunodominance of HIV-1-specific CTL epitopes among three subtypes of HLA-A*26 associated with slow progression to AIDS.
    Biochem Biophys Res Commun, 366(3): 612-6. [Abstract] [Full-text]
15. SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag.
    Proc Natl Acad Sci U S A, 105(1): 294-9. [Abstract] [Full-text]
16. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
    Clin Infect Dis, 46(3): 361-6. [Abstract] [Full-text]
17. Mechanistic insights into the role of Val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis.
    J Mol Biol, 375(5): 1234-48. [Abstract] [Full-text]
18. Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).
    Bioorg Med Chem, 16(1): 157-63. [Abstract] [Full-text]
19. Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.
    Bioorg Med Chem, 16(1): 511-7. [Abstract] [Full-text]
20. Human immunodeficiency type-1 virus (HIV-1) infection in serodiscordant couples (SDCs) does not have an impact on embryo quality or intracytoplasmic sperm injection (ICSI) outcome.
    Fertil Steril, 89(1): 141-50. [Abstract] [Full-text]
21. Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection.
    Immunology, 123(2): 164-70. [Abstract] [Full-text]
22. Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy.
    AIDS, 22(3): 427-30. [Abstract] [Full-text]
23. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    AIDS, 22(3): 367-76. [Abstract] [Full-text]
24. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    AIDS, 22(3): 339-48. [Abstract] [Full-text]
25. Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired fitness.
    J Infect Dis, 197(2): 300-8. [Abstract] [Full-text]
26. Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus.
    J Infect Dis, 197(2): 309-18. [Abstract] [Full-text]
27. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
    Nat Rev Microbiol, 6(2): 143-55. [Abstract] [Full-text]
28. Insight into the intrinsic flexibility of the SL1 stem-loop from genomic RNA of HIV-1 as probed by molecular dynamics simulation.
    Biopolymers, 89(3): 187-96. [Abstract] [Full-text]
29. Cooperative binding of the class I major histocompatibility complex cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu subunit.
    J Virol, 82(3): 1249-58. [Abstract] [Full-text]
30. Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections.
    J Virol, 82(3): 1155-65. [Abstract] [Full-text]
31. Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro.
    J Virol, 82(3): 1425-37. [Abstract] [Full-text]
32. A diacidic motif in human immunodeficiency virus type 1 Nef is a novel determinant of binding to AP-2.
    J Virol, 82(3): 1166-74. [Abstract] [Full-text]
33. Human immunodeficiency virus type 1 Gag engages the Bro1 domain of ALIX/AIP1 through the nucleocapsid.
    J Virol, 82(3): 1389-98. [Abstract] [Full-text]
34. Gag-processing defect of human immunodeficiency virus type 1 integrase E246 and G247 mutants is caused by activation of an overlapping 5' splice site.
    J Virol, 82(3): 1600-4. [Abstract] [Full-text]
35. Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex.
    J Virol, 82(3): 1229-37. [Abstract] [Full-text]
36. Species-specific restriction of apobec3-mediated hypermutation.
    J Virol, 82(3): 1305-13. [Abstract] [Full-text]
37. The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4.
    Biochem Biophys Res Commun, 367(1): 41-6. [Abstract] [Full-text]
38. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Clin Infect Dis, 46(4): 611-21. [Abstract] [Full-text]
39. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles.
    Clin Infect Dis, 46(4): 523-7. [Abstract] [Full-text]
40. Factors associated with HIV seroconversion in gay men in England at the start of the 21st century.
    Sex Transm Infect, 84(1): 8-13. [Abstract] [Full-text]
41. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision.
    Mol Pharmacol, 73(2): 601-6. [Abstract] [Full-text]
42. Disease severity, self-reported experience of workplace discrimination and employment loss during the course of chronic HIV disease: differences according to gender and education.
    Occup Environ Med, 65(2): 112-9. [Abstract] [Full-text]
43. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Nature, 451(7177): 425-30. [Abstract] [Full-text]
44. Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro.
    J Med Virol, 80(3): 494-500. [Abstract] [Full-text]
45. Comparison between Sendai virus and adenovirus vectors to transduce HIV-1 genes into human dendritic cells.
    J Med Virol, 80(3): 373-82. [Abstract] [Full-text]
46. Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools.
    J Med Virol, 80(3): 383-91. [Abstract] [Full-text]
47. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
    J Pharmacol Exp Ther, 324(2): 558-67. [Abstract] [Full-text]
48. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics.
    J Virol, 82(4): 1870-83. [Abstract] [Full-text]
49. Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses.
    J Virol, 82(4): 1923-33. [Abstract] [Full-text]
50. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.
    J Virol, 82(4): 1860-9. [Abstract] [Full-text]
51. An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort.
    J Virol, 82(4): 1980-92. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.